Daniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, Hernando Knobel, Mar Masiá, Chiara Fanciulli, Cristina Hernández, María Lagarde, Angela Gutierrez, Adrià Curran, Luis Morano, Marta Montero-Alonso, Jesús Troya, Raúl Rigo, María Casadellà, Antonio Navarro-Alcaraz, Fernando Ardila, Mariona Parera, Enrique Bernal, Patricia Echeverria, Vicente Estrada, Carmen Hidalgo-Tenorio, Juan Macias, Paula Prieto, Joaquín Portilla, Eulalia Valencia, María Jesús Vivancos, Antonio Rivero
OBJECTIVES: To evaluate the efficacy and safety of the two-pill regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching strategy in heavily treatment-experienced people living with HIV (PLWH). METHODS: Multicentre, prospective, single-arm pilot clinical trial. Participants were virologically suppressed adults receiving a stable antiretroviral regimen of at least three pills from at least three drug families due to previous virological failures and/or toxicities with no documented resistance to integrase strand transfer inhibitors or darunavir (≥15 points, Stanford)...
September 19, 2023: Journal of Antimicrobial Chemotherapy